Cargando…

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052

Detalles Bibliográficos
Autores principales:	Smirnov, DV, Zhao, G, Beaurline, JM, Johnson, KE, Capecchi, JT, Harrison, LI, Tomai, MA, Elvecrog, JM, Klinman, DM, Vasilakos, JP
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991061/ http://dx.doi.org/10.1186/2051-1426-1-S1-P138

Ejemplares similares

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
por: Mullins, Stefanie R., et al.
Publicado: (2019)

Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy
por: Boss, Mary-Keara, et al.
Publicado: (2022)

TLR Agonist Therapy of Metastatic Breast Cancer in Mice
por: Klinman, Dennis M., et al.
Publicado: (2023)

Induction of systemic anti-melanoma immunity through intratumoral TLR-7/8 activation
por: Singh, Manisha, et al.
Publicado: (2014)

A "prime-pull" immunotherapy approach using a lentiviral vector and intratumoral TLR4 agonist redirects cytotoxic T cells
por: Albershardt, Tina C, et al.
Publicado: (2014)

Comparison of human B cell activation by TLR7 and TLR9 agonists
por: Hanten, John A, et al.
Publicado: (2008)

Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists
por: Andón, Fernando Torres, et al.
Publicado: (2022)

Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐negative breast cancer
por: Zanker, Damien J, et al.
Publicado: (2020)

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
por: Lee, Won Suk, et al.
Publicado: (2022)

Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors
por: Albershardt, Tina C., et al.
Publicado: (2020)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach
por: Fox, Christopher B., et al.
Publicado: (2016)

Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2020)

Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists
por: Birmachu, Woubalem, et al.
Publicado: (2007)

Title unknown, CERN-ALEPH-87-052
por: Knobloch, J
Publicado: (1987)

Intratumoral Immunotherapy—Update 2019
por: Hamid, Omid, et al.
Publicado: (2019)

Trial watch: intratumoral immunotherapy
por: Humeau, Juliette, et al.
Publicado: (2021)

Immunotherapeutic Agents for Intratumoral Immunotherapy
por: Shyr, Chih-Rong, et al.
Publicado: (2023)

Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors
por: Zhao, By Gan, et al.
Publicado: (2014)

Correction to: Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2021)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
por: Younes, Ahmed I., et al.
Publicado: (2020)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Characterization of intratumor microbiome in cancer immunotherapy
por: Zhang, Zhao, et al.
Publicado: (2023)

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine
por: Tran, Christine A, et al.
Publicado: (2023)

TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
por: Lu, Hailing
Publicado: (2014)

Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma
por: Deng, Shuanglin, et al.
Publicado: (2014)

Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy
por: Rodell, Christopher B., et al.
Publicado: (2019)

The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview
por: Veneziani, Irene, et al.
Publicado: (2022)

Live-Attenuated VEEV Vaccine Delivered by iDNA Using Microneedles Is Immunogenic in Rabbits
por: Tretyakova, Irina, et al.
Publicado: (2022)

Repurposing infectious disease vaccines for intratumoral immunotherapy
por: Melero, Ignacio, et al.
Publicado: (2020)

Repurposing the yellow fever vaccine for intratumoral immunotherapy
por: Aznar, Maria Angela, et al.
Publicado: (2019)

The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy
por: Brito-Orama, Sebastian, et al.
Publicado: (2023)

Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano‐Immunoadjuvant
por: Wei, Jingjing, et al.
Publicado: (2022)

Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A
por: Lu, Hailing, et al.
Publicado: (2020)

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
por: Carbone, Carmine, et al.
Publicado: (2021)

Intratumoral expression of IL-12 from lentiviral or RNA vectors acts synergistically with TLR4 agonist (GLA) to generate anti-tumor immunological memory
por: Leleux, Jardin A., et al.
Publicado: (2021)

Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Carroll, Christina S E, et al.
Publicado: (2021)

Intratumoral cancer immunotherapy exploiting anti-viral immunity
por: Kadowaki, Norimitsu
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3t9m76avmodbivofskq6mbrvh6